Clinical Trials
11 trialsNCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT05054725 2026-01-06
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Phase 2 Completed
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT04512430 2025-04-02
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
Phase 2 Terminated
NCT02264210 2024-09-25
CORIN
Sun Yat-sen University
Phase 2 Completed
NCT02826161 2023-11-15
CanStem43L
Sumitomo Pharma America, Inc.
Phase 3 Terminated
NCT02904954 2023-10-11
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer
Weill Medical College of Cornell University
Phase 2 Completed
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT02134015 2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3 Terminated